SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is seeing significant volatility as investors weigh strong quarterly earnings and improved advertising momentum against negative sentiment from insider selling and a court ruling allowing lawsuits over youth platform safety to proceed. The community remains deeply divided, with bulls pointing to the company's path toward profitability and AR product potential, while bears focus on long-term management concerns and the impact of insider stock sales.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors react to the company's clear regulatory pathway for AXPAXLI, with management confirming an upcoming NDA submission following productive alignment with the FDA. The community is heavily focused on the implications of the upcoming Investor Day, debating the potential for a buyout, commercialization strategy, and the relative competitive positioning of the drug's sustained-release hydrogel technology against other market participants.

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is trending following a failed primary endpoint in the pivotal LUGANO Phase 3 trial for its wet AMD candidate, DURAVYU, triggering significant volatility and investor anxiety. The community is actively debating the trial's ad-hoc efficacy results versus the clinical failure, while many investors are rotating into competitor Ocular Therapeutix (OCUL) in anticipation of a potential shift in market dominance.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as market participants weigh strong AI-driven growth metrics and potential catalysts, such as the spin-off of its chip unit, against persistent skepticism regarding geopolitical risks and historical underperformance in Chinese equities. Community discourse remains deeply divided between long-term investors highlighting deep-value fundamentals and bearish traders pointing to a perceived head-and-shoulders chart pattern and ongoing regulatory headwinds.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris Technologies is trending following the announcement of a strategic partnership with the Department of War to expand solid rocket motor production through a $1 billion investment, which includes plans for an IPO of its Missile Solutions unit in late 2026. Investors are closely monitoring the stock as it gains momentum from this potential deconsolidation and the broader defense industry's pivot toward high-demand propulsion systems.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors monitor the imminent 80th event in the Phase 3 REGAL trial, which serves as the final catalyst for unblinding survival data. The community is intensely debating the significance of the extended trial timeline, with many interpreting the delay as strong evidence of the treatment's efficacy against AML while actively discussing institutional accumulation and potential buyout scenarios.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almonty Industries is gaining strong momentum as investors react to the company's progress in commissioning its Sangdong tungsten mine, a critical asset for Western supply chain independence. The community is actively discussing the stock's role in defense and semiconductor manufacturing, noting increased institutional accumulation and rising global tungsten prices as key catalysts for growth.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is gaining attention as investors debate its valuation relative to sector leaders like CrowdStrike and Palo Alto Networks, with many highlighting its advanced AI security technology and potential as a standalone growth asset or buyout target. The community is actively discussing the stock's significant discount compared to its peers, the strategic value of its Anthropic equity stake, and the anticipation of institutional confidence during upcoming earnings cycles.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

Vanguard S&P 500 ETF (VOO) continues to track the broader market's upward momentum as investors balance optimism over potential geopolitical de-escalation with ongoing concerns regarding valuations and debt levels. The community is actively debating the sustainability of the current rally, with some investors favoring continued accumulation through disciplined dollar-cost averaging while others warn of potential bubble risks in the current rate environment.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the company's progress toward a BLA submission for its prostate cancer therapy, CAN-2409, and clinical advancements in lung cancer treatments. Community discussion is heavily centered on the potential for massive addressable market growth, institutional accumulation, and strong confidence in management's ability to navigate the upcoming regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Invesco Actively Managed Exchange-Traded Fund Trust - Invesco Managed Futures Strategy ETF

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$52.65
Prev Close	$52.39
Open	$52.75
Dividend Yield	N/A
50-Day Moving Average	$51.61
Beta	N/A
Avg. Volume	11,329.89
PE Ratio	N/A

52-Week High	$55.71
52-Week Low	$43.60
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info